Related Experiment Video
Updated: Jun 22, 2026
10:00
High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
Published on: March 24, 2015
Improving compliance with interferon-beta therapy in patients with multiple sclerosis
Emilio Portaccio1, Maria Pia Amato
1Department of Neurology, University of Florence, Florence, Italy. portilio@tin.it
CNS Drugs
|June 2, 2009
Summary
Interferon-beta (IFNbeta) therapies are used for relapsing-remitting multiple sclerosis (RRMS). New formulations aim to improve tolerability and adherence, addressing common side effects and discontinuation rates in RRMS patients.
Area of Science:
- Neurology
- Immunology
- Pharmacology
Background:
- Multiple sclerosis (MS) is an inflammatory demyelinating disease primarily affecting young adults.
- Relapsing-remitting MS (RRMS) is characterized by inflammatory phases followed by progressive disability.
- Interferon-beta (IFNbeta) therapies are first-line treatments for RRMS, reducing relapses and disability progression.
Purpose of the Study:
- To review current Interferon-beta (IFNbeta) formulations for relapsing-remitting multiple sclerosis (RRMS).
- To discuss challenges in IFNbeta therapy, including discontinuation rates due to adverse effects and poor compliance.
- To explore newer IFNbeta formulations designed to improve tolerability and patient adherence.
Main Methods:
- Review of existing literature on IFNbeta therapies for RRMS.
- Analysis of clinical trial data for novel IFNbeta formulations.
- Discussion of factors influencing patient adherence and treatment discontinuation.
Main Results:
- Current IFNbeta formulations (IFNbeta-1a and IFNbeta-1b) reduce relapses but have significant discontinuation rates (14-44%) due to side effects like flu-like syndrome and injection site reactions.
- Newer formulations like Biferonex(R) and Rebif(R) New Formulation (RNF) aim to reduce immunogenicity and improve tolerability.
- RNF demonstrated higher tolerability, especially regarding injection site reactions, compared to older formulations in a phase III trial.
Conclusions:
- Improving adherence to IFNbeta therapy requires individualized patient education and support involving a multidisciplinary team.
- Novel IFNbeta formulations, such as RNF, offer potential for better tolerability and adherence in RRMS patients.
- Further research is needed to confirm the utility of new IFNbeta formulations, particularly for patients intolerant to existing treatments.
Related Concept Videos
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...